ClinicalTrials.govpublic full text
CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes
diabetes mellitus, type 2, obesity, post-bariatric surgery, hemoglobin a1c protein, human, interventional, phase4
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 833618
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.